NCT00634361View on ClinicalTrials.gov

Ethyl-EPA Treatment of Prodromal Patients

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions

Schizophrenia Prodrome

Interventions

DRUG

ethyl-eicosapentaenoic acid

2 mg per day

All Listed Sponsors

lead

Yale University

OTHER

NCT00634361 - Ethyl-EPA Treatment of Prodromal Patients | Biotech Hunter | Biotech Hunter